Stoke Therapeutics Inc

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced highlights from presentations being made at the American Epilepsy Society (AES) 2020 Virtual Annual Meeting December 4-8, 2020 related to the Company's work to advance STK-001, the first potential new medicine to target the underlying cause of Dravet syndrome. Dravet

Stoke Therapeutics Announces Presentations Related to the Company's Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting

Coty

Danaher

Foot Locker

Biglari Hlds

Biohaven Pharmaceutical Hld

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets, as there was before and after the elections and as the pandemic worsens.

Notable Insider Buys in the Past Week: Biglari, Coty, Danaher, Foot Locker And More

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that four abstracts related to the Company's work in Dravet syndrome have been selected for presentation at the upcoming American Epilepsy Society (AES) 2020 Virtual Annual Meeting, taking place December 4 – 8, 2020. Dravet syndrome is a severe and progressive genetic

Stoke Therapeutics Announces Presentations Related to the Company's Work in Dravet Syndrome at the American Epilepsy Society 2020 Virtual Annual Meeting

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the closing of its underwritten public offering of 2,875,000 shares of its common stock, including 375,000 shares sold upon full exercise of the underwriters' option to purchase additional shares, at a price to the public of $39.00 per share. The net proceeds from the

Stoke Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $39.00 per share. The gross proceeds from this offering are expected to be $97.5 million, before deducting underwriting discounts and commissions and oth

Stoke Therapeutics Announces Pricing of $97.5 Million Public Offering

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020, at 3:20 p.m. ET. A live audio webcast of the presentation will be available on the Investors & Media sect

Stoke Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will participate in a fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference on Monday, November 9, 2020, at 10:15 a.m. ET. A live audio webcast of the fireside chat will be avail

Stoke Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced plans to move forward with dosing of STK-001 in children and adolescents in its ongoing Phase 1/2a MONARCH study for Dravet syndrome. Following recent interactions with the U.S. Food and Drug Administration (FDA) related to the partial clinical hold on

Stoke Therapeutics Announces Plans to Move Forward With Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1/2a MONARCH Study for Dravet Syndrome

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc.

Stoke Therapeutics to Present at Cantor Virtual Global Healthcare Conference

Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine that Demonstrate Significant Improvements in Survival and Reductions in Seizure Frequency in a Dravet Syndrome Mouse Model

Stoke Therapeutics Announces Appointment of Garry E. Menzel, Ph.D.

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases, today announced the publication of data in the journal Nature Communications that support the company’s proprietary approach to precisely upregulate protein expression using TANGO (Targeted Augmentation of Nuclear Gene Output) antisense oligonucleotides (ASOs). “Stoke was founded on the idea that we could use unique insi

Stoke Therapeutics Announces Publication of Data in the Journal Nature Communications That Support the Company’s Proprietary Approach to Addressing Severe Genetic Diseases by Precisely Upregulating Protein Expression

As of late, it has definitely been a great time to be an investor Stoke Therapeutics, Inc. (STOK).

Stoke Therapeutics, Inc. (STOK) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor Stoke Therapeutics.

Can The Uptrend Continue for Stoke Therapeutics?

Will Stoke Therapeutics Continue to Surge Higher?

After top performance in August, the biotech was hit hard.

Why Shares of Stoke Therapeutics Plummeted in September

Eidos Therapeutics Inc

Can their share prices continue to climb?

3 New Biotech Stocks That Keep On Soaring

Stoke Therapeutics Inc. shares rocketed 46% in their trading debut Wednesday, after the company's initial public offering priced above its $14 to $16 price range.

Stoke Therapeutics shares soar 46% in trading debut

Stoke Therapeutics, Inc. opened Wednesday morning at $27.21 per share.

Stoke Therapeutics Opens Above IPO Price

News for Stoke Therapeutics Inc Stock (STOK)